DiNardo CD et al. A randomized, double-blind, placebo-controlled study of venetoclax with azacitidine vs azacitidine in treatment-naïve patients with acute myeloid leukemia ineligible for intensive therapy — VIALE-A. EHA 2020;Abstract LB2601.
DiNardo CD et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 2020;383(7):617-29. Abstract
DiNardo C et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med 2018;378(25):2386-98. Abstract
Dohner H et al. Escalated dosing schedules of CC-486 are effective and well tolerated for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial. ASH 2020;Abstract 111.
Fenaux P et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med 2020;382(2):140-51. Abstract
Garcia JS et al. Safety, efficacy, and patient-reported outcomes of venetoclax in combination with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome: A Phase 1b study. ASH 2020;Abstract 656.
Garcia-Manero G et al. Oral cedazuridine/decitabine for MDS and CMML: A phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. Blood 2020;136(6):674-83. Abstract
Kadia TM et al. Phase II study of CPX-351 plus venetoclax in patients with acute myeloid leukemia (AML). ASH 2020;Abstract 28.
Konopleva M et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov 2016;6(10):1106-17. Abstract
Lancet JE et al. Five-year final results of a phase III study of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML. ASCO 2020;Abstract 7510.
Lancet JE et al. Five-year final results of a phase 3 study of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary acute myeloid leukemia (AML): Outcomes by age subgroup and among responders. ASH 2020;Abstract 635.
Lin TL et al. Phase 1b/2 study of venetoclax with low-dose cytarabine in treatment-naive patients aged 65 years with acute myelogenous leukemia. ASCO 2016;Abstract 7007.
Perl AE et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med 2019;381(18):1728-40. Abstract
Roboz GJ et al. Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia. Leuk Lymphoma 2020;61(5):1188-94. Abstract
Sallman DA et al. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results. ASCO 2020;Abstract 7507.
Sekeres MA, Cutler C. How we treat higher-risk myelodysplastic syndromes. Blood 2014;123(6):829-36. Abstract
Steensma DP et al. Imetelstat achieves meaningful and durable transfusion independence in high transfusion-burden patients with lower-risk myelodysplastic syndromes in a phase II study. J Clin Oncol 2021;39(1):48-56. Abstract
Stein E et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood 2019;133(7):676-87. Abstract
Tardi P et al. In vivo maintenance of synergistic cytarabine: Daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res 2009;33(1):129-39. Abstract
Wei AH et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med 2020;383(26):2526-37. Abstract
Wei AH et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: A phase 3 randomized placebo-controlled trial. Blood 2020;135(24): 2137-45. Abstract